Inducements in Research (Undue Inducement)

An inducement in research ethics is any payment, benefit, or other incentive offered to encourage someone to enroll in, or remain enrolled in, a study. Offering participants compensation is standard practice and is not, on its own, an ethical problem. The concern IRBs are specifically required to review for is undue inducement: a payment or benefit so large, or structured in a way, that it impairs a prospective participant’s ability to weigh the study’s risks and benefits rationally, effectively overriding rather than informing their decision to consent.

Where this sits in the Belmont Report’s framework

The Belmont Report (1979) grounds this concern in two of its three core principles. Respect for persons requires that consent be truly voluntary; beneficence requires that risks be reasonable relative to anticipated benefits, and payment is not counted as an offsetting benefit in that risk-benefit calculus. Its regulatory implementation, the Common Rule at 45 CFR 46 Section 46.111(b), requires an IRB to determine that consent will be sought under circumstances that minimize the possibility of coercion or undue influence before it can approve a study. Payment is only one channel for that pressure; deferential vulnerability covers the parallel risk that a participant simply defers to a treating clinician or supervisor. FDA-regulated research applies a parallel requirement at 21 CFR 50.20. Reviewing the proposed payment amount, schedule, and any completion contingency is the concrete way IRBs make that determination when the influence in question is a financial or in-kind offer specifically — as distinct from coercion (a threat of harm for refusing) or other non-payment forms of undue influence.

What makes an inducement “undue”

There is no fixed dollar threshold in federal regulation; undue inducement is a judgment IRBs make case by case, weighing the payment against the study’s actual risk profile and the population being recruited. Recurring factors IRBs weigh include:

• Size relative to risk — a payment that is large relative to a low-risk study’s actual burden is more likely to be flagged than the same amount for a demanding, higher-burden protocol.
• Contingency structure — payment withheld entirely until study completion, or forfeited on withdrawal, creates pressure to remain enrolled (or to under-report symptoms) independent of ongoing risk tolerance. FDA guidance and OHRP/SACHRP recommend prorating payment across a study’s duration rather than delaying it to completion, and allowing a small completion bonus on top of already-accrued payment rather than making the entire sum contingent.
• Vulnerability of the population — the same payment can weigh differently for participants with significant financial need, echoing the Belmont Report’s concern for vulnerable populations and the additional safeguards Common Rule Subparts B-D require for some of them.
• Disclosure — the amount and payment schedule must themselves be disclosed in the informed consent document, both because it is a required consent element and so the IRB (and the participant) can evaluate it.

Inducement is not the same as coercion or undue influence generally

These three terms are related but distinct in IRB review vocabulary. Coercion is an explicit or implicit threat of harm for refusing to participate — for example, a treating physician implying that declining a trial will affect a patient’s ongoing clinical care. Undue influence is the broader category: any excessive, unwarranted, or otherwise inappropriate reward or overture used to obtain compliance, which can include non-monetary pressure (e.g. from a position of authority) as well as payment. Undue inducement is the payment-specific instance of undue influence — the concern this term addresses.

Practical guidance sources

Two federal sources IRBs and sponsors commonly reference when structuring participant payment: FDA’s “Payment and Reimbursement to Research Subjects” guidance for IRBs and investigators (issued January 2018), and OHRP/SACHRP’s “Attachment A: Addressing Ethical Concerns Regarding Offers of Payment to Research Participants” (finalized 2019). Both distinguish reimbursement of costs already incurred (travel, parking, lodging) — which does not by itself raise undue-influence concerns — from compensation offered as a recruitment incentive, which does need to be evaluated against the factors above.

Related terms

• Belmont Report
• Informed Consent in Research
• IRB (Institutional Review Board)
• Common Rule (45 CFR 46)
• Vulnerable Populations in Research

Frequently Asked Questions

Is it unethical to pay people to take part in a research study?

No. Offering compensation to research participants is standard practice and is not, on its own, an ethical problem. The concern IRBs review for is specifically undue inducement — a payment large enough, or structured in a way, that it overrides rather than informs a prospective participant’s decision to consent.

Is undue inducement easy for an IRB to determine?

No. There is no fixed dollar threshold in federal regulation. Undue inducement is a judgment IRBs make case by case, weighing the proposed payment against the study’s actual risk profile and the population being recruited.

How is undue inducement different from coercion?

Coercion is an explicit or implicit threat of harm for refusing to participate — for example, a treating physician implying that declining a trial will affect a patient’s clinical care. Undue inducement is payment-specific: it is the subset of undue influence that arises from an excessive or inappropriately structured financial or in-kind offer rather than a threat.

What factors do IRBs weigh when reviewing participant payment?

Recurring factors include the payment’s size relative to the study’s actual risk and burden, whether payment is contingent on completion (which can pressure participants to stay enrolled or under-report symptoms), the vulnerability of the population being recruited, and whether the amount and payment schedule are disclosed in the informed consent document.

Is reimbursing a participant’s travel costs considered an inducement?

Reimbursement of costs a participant has already incurred — travel, parking, lodging — does not by itself raise undue-influence concerns. That is distinct from compensation offered specifically as a recruitment incentive, which does need to be evaluated against factors like payment size, contingency structure, and the population’s vulnerability.

Does a contingent or completion-only payment structure raise undue-influence concerns?

Yes. Withholding payment entirely until study completion, or forfeiting it on withdrawal, creates pressure to remain enrolled independent of a participant’s ongoing risk tolerance. Guidance from FDA and OHRP/SACHRP recommends prorating payment across a study’s duration and limiting any completion bonus to a small addition on top of already-accrued payment, rather than making the entire sum contingent.